skip to main content
Global Search Configuration
Master the nuances of accelerated approval processes for the US and Europe with coverage from Pink Sheet. Go inside the competitive landscape to learn which drugs are benefitting from such programs – and which are not. Pink Sheet delivers the insider’s view of European fast-track programs like PRIME – plus updates on US FDA expedited reviewal processes – you can use to inform your own regulatory strategy.


Europe’s fast track

Go inside Europe’s accelerated approval programs with up-to-date insights from Pink Sheet.

Pink Sheet takes you inside European programs, including PRIME and Europe’s accelerated assessment program, to bring you details on how drug developers are using these difficult-to-obtain designations to reach market faster. Learn about updates to the programs and how they are impacting specific products on the European market.  
Accelerated Approvals European Coverage

Updates and insight into expedited reviews

Understand the increasingly complicated world of US FDA fast-track approvals programs.

Gain a window into the expedited review programs from US FDA, which have grown from the long-standing accelerated approval program to include new designations and new considerations in other similar programs. Stay up to date with this evolving area and develop your own successful regulatory strategy using news and insight from Pink Sheet. 
Accelerated Approvals US Coverage

Read also


Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: